Devil's in the details for doctor transparency
The Atlantic, July 3, 2012
Every drug, device or medical supply company must report transfers of value that exceed $10 to the new federal database maintained by the Centers for Medicare and Medicaid Services (CMMS). Last month CMMS announced it's delaying implementation until January 2013 to allow it more time to create the needed infrastructure, but at least twelve companies are already reporting payments in a less uniform and streamlined fashion. A database maintained by ProPublica makes this data easy to search for interested citizens and healthcare reporters. The ProPublica database has raised important questions for academic medical centers replete with physicians who serve as pharmaceutical company spokespeople.
Most Viewed
Most Emailed
- $6.4B Henry Ford, Beaumont Merger Failed on Cultural Hurdles
- Don't Let Nurses Sink Your Bottom Line
- Hospitals Profit On Bloodstream Infections
- Fortunately, Angelina Jolie Isn't On Medicare
- Less Blood Testing for Some Surgeries Safe, Cost Effective
- Lower ED Margins Demand a Better Strategy
- How Chargemaster Data May Affect Hospital Revenue
- Primary Care Docs Average More Hospital Revenue Than Specialists
- House Lawmakers Grill CMS Over Health Exchange Navigators
- ED Physicians Key to Half of Hospital Admissions
